Researchers found "no increased risk of invasive cervical cancer or high-grade cervical intraepithelial neoplasia in transmasculine and gender-diverse (TMGD) [individuals] using gender-affirming hormone therapy," but added that the findings should be interpreted with caution.
"Testosterone therapy in hypogonadal men showed no reduction in fracture risk, with fracture incidence higher in the treatment group, researchers reported."
Investigational drug in combination with weight-loss treatment preserves lean muscle mass in older patients with obesity, showing promising potential for reducing adiposity and achieving greater weight reduction.